Allergan settles with one of four companies contesting Restasis patent
(Reuters) - Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute
Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Mylan says Allergan misusing tribal sovereignty in patent dispute
NEW YORK (Reuters) - Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis. (Source: Reuters: Health)
Source: Reuters: Health - September 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Allergan pays Mohawk Tribe to protect patents from challenges
(Reuters) - Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. (Source: Reuters: Health)
Source: Reuters: Health - September 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Shire applies for European approval of potential blockbuster eye drop
One of the state ’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S.
The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016 . It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2017 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
Gengraf Capsules (Cyclosporine Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 11, 2017 Category: Drugs & Pharmacology Source Type: news
Allergan, Argentum settle patent dispute over eye drug Restasis
(Reuters) - U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis. (Source: Reuters: Health)
Source: Reuters: Health - April 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Allergan Announces Availability of RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
DUBLIN, March 22, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) today announced the availability of RESTASIS MULTIDOSE, which is the same preservative-free RESTASIS® formulation, but now offered in a multidose bottle. RESTASIS&... Biopharmaceuticals, Ophthalmology, Product Launch Allergan, RESTASIS, Cyclosporine, Chronic Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news
Disseminated Nocardia farcinica Infection in a Patient with Steroid-dependent Autoimmune Hemolytic Anemia: Case Report and Literature Review
We describe a 64-year-old female with autoimmune hemolytic anemia (AIHA) who was steroid dependent and on cyclosporine immunosuppressive therapy. Nocardia farcinica was recovered from the patient's bronchoalveolar lavage (BAL) specimen and several blood cultures. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - January 20, 2017 Category: Microbiology Authors: Zeti Norfidiyati Ayub, Habsah Hasan, Mohd Zulfakar Mazlan, Alwi Muhd Besari Tags: Case Report Source Type: news
Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab
Long-term outcomes of patients with steroid-refractory acute severe ulcerative colitis (UC) are similar whether treated with cyclosporine or infliximab, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Mylan, Allergan launch fight over Restasis eye drop patents
Allergan (NYSE:AGN) said this week that it will “vigorously defend” the patents for its Restasis eye drops, after the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board agreed to an inter partes review of 6 patents as requested by generic competitor Mylan (NSDQ:MYL). The patents are valid until August 2024.
“Allergan is disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that protect Restasis,” the company wrote in a statement yesterday. “Allergan is currently reviewing the grounds for the decision to institute, and will continue to...
Source: Mass Device - December 9, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news
Gengraf Oral Solution (Cyclosporine Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news
Neoral (Cyclosporine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news
Allergan asks FDA to approve Oculeve neurostim device
Allergan (NYSE:AGN) said today that it filed a de novo approval application with the FDA for its Oculeve nasal neurostimulation device for dry eye it bought last year.
Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year.
The de novo protocol is for low- to moderate-risk devices that don’t have a “substantially equivalent predecessor” device already on the market.
“The Oculeve intranasal tear neurostimulator is an exciting potential option for patients suffering f...
Source: Mass Device - July 18, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Optical/Ophthalmic Regulatory/Compliance Allergan Inc. Oculeve Source Type: news
Cyclosporine of No Benefit in Cardiac Arrest (CME/CE)
(MedPage Today) -- Drug failed to improve outcomes in nonshockable patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 15, 2016 Category: Cardiology Source Type: news
